Inaugural ERSAP Prize Awarded to Pat Garcia-Gonzalez

Estoril, Portugal–

In recognition of her personal contribution and role in leading The Max Foundation in increasing access to treatment, care, and support for people living with cancer around the world, Max CEO, Pat Garcia-Gonzalez is the first recipient of the International Chronic Myeloid Leukemia (CML) Foundation’s ERSAP Prize.

The International CML Foundation awarded our CEO Pat Garcia-Gonzalez with the inaugural ERSAP (Emerging Region Support and Partnership) Prize at the 17th annual John Goldman CML Conference co-sponsored by the iCMLf and the European School of Haematology. The iCMLf Directors and Scientific Advisors selected Pat because of her continued commitment, and The Max Foundation’s aim, to help people face cancer with dignity and hope.

Tim Hughes, iCMLf Chair, stated, “Pat strongly believes that people living with CML have the right to access the best possible treatment and support, wherever they live. This is why she has been so determined to make new drugs for CML fully available to patients in emerging economic regions through access programs, education and global advocacy efforts.”

“I am honored to receive the first ever ERSAP Prize and thank our partners at the International CML Foundation for their recognition.” Pat stated. “I take this award as an opportunity to reflect on how providing access to life-saving treatments to people around the world makes our global community stronger and a more just place to live. There are still so many people around the world who deserve our advocacy and support and we carry out our work on their behalf. This award reignites our commitment for finding innovative solutions to help people face cancer with dignity and hope.”

iCMLf award announcement.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

    The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

    SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the….

  • Spot On CML Grows in the Philippines

    Spot On CML Grows in the Philippines

    Today, Spot On CML is active in 19 countries and, on June 29th, 17 patients were chosen by the treating physicians at Philippine General Hospital to take part in the program. While CML testing is available in the Philippines, it’s prohibitively expensive – placing critical diagnostic information out of reach for many patients.

  • CancerWorld Special Issue

    CancerWorld Special Issue

    We’re excited to announce our collaboration with CancerWorld magazine! This special issue is about the 25th anniversary of an oral medication for chronic myeloid leukemia that transformed treatment, diagnostics, access, and patient advocacy. It features articles from the global community, including clinicians, researchers, patients, and advocates. Learn more about how a woman living with CML….